Increased Cypher Shipments Unhindered By Cordis Warning Letter – J&J Exec
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson will ramp up inventory of the Cypher sirolimus-eluting stent to fulfill existing back-orders over the next several weeks
You may also be interested in...
Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events
Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector
Cordis Recalls 300 Underweight Cypher Units, Predicts Zero Adverse Events
Johnson & Johnson/Cordis' 300-unit recall of its Cypher sirolimus-eluting stent from 145 centers nationwide marks the most recent manufacturing glitch for the high-profile sector
Boston Scientific Taxus Japan Launch Delayed Until Second Half Of 2006
Boston Scientific will begin a required Japanese premarket approval trial next year for its Taxus paclitaxel-eluting stent, incorporating a short-term endpoint of major adverse coronary events (MACE)